› On 1 June 2025, a Poster titled Early detection of ovarian cancer: An accurate high-throughput extracellular vesicle test was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (ASCO poster and published abstract). › On 2 June 2025, INOVIQ announced game-changing results from its EXO-OC™ ovarian cancer test that demonstrated 77% sensitivity at >99.6% specificity for detection of ovarian cancer across all stages, meeting the clinically accepted performance criteria for effective population screening. Importantly, the test accurately detected 100% Stage I and II ovarian cancers, with no missed early-stage diagnoses. These miRNA biomarker results were achieved by INOVIQ working with leading computational scientist, Prof Amanda Barnard, to independently analyse the miRNA biomarker data and develop advanced AI machinelearning algorithms to enhance the detection of earlystage ovarian cancer (Stage I and II). 100% 100% 100% 100% 79% 50% 50% 77.4% controls benign Stage I Stage II Stage III Stage IV na overall percent speci city sensitivity The EXO-OC test can be run on fully-automated, high-throughput, instrument platforms suitable for clinical pathology laboratories worldwide. INOVIQ is currently engaging with potential clinical laboratory and diagnostic partners to expedite the development and commercialisation of the test, first as a Laboratory Developed Test (LDT) in late 2026 and then as a regulatory approved In Vitro Diagnostic (IVD) kit in the US, Europe and Asia Pacific from 2028. EXOSOME THERAPEUTICS – NEXT GENERATION CAR-EV THERAPY INOVIQ’s exosome therapeutics program uses chimeric antigen receptor (CAR)-exosomes that are released from genetically engineered immune cells. CARexosomes have potential as cell-free therapeutics with manufacturing, safety and efficacy advantages over autologous cell therapies for treating solid tumours. CAR-exosomes inherit the tumour-targeting and cytotoxic capabilities of their parent CAR-T/NK cells, specifically targeting and killing cancer cells. INOVIQ’s first CAR-NK-exosome therapy is in preclinical development for triple negative breast cancer (TNBC). There are no approved targeted therapeutics available for TNBC, with the current standard of care being chemotherapeutics. During the year, INOVIQ established its robust production process for therapeutic exosomes that target and kill breast cancer cells including establishing Master Cell Banks of engineered CAR-NK cell lines, optimising its proprietary EXO-ACE™ technology to isolate therapeutic exosomes, validating CAR expression on its CAR-NKexosomes and demonstrating in vitro cancer killing efficacy. › On 16 December 2024, INOVIQ announced that it had achieved in vitro proof-of-concept (POC) for its CARNK-exosomes demonstrating dose dependent cancer cell death and over 30% breast cancer cell death in vitro at the highest dose evaluated. › On 31 March 2025, INOVIQ announced that it has engaged Peter Mac to further validate its CARexosome therapy to treat solid tumours. INOVIQ signed a Master Service Agreement (MSA) with Peter Mac to provide contract research services under separate Statements of Work (SOW) to undertake in vitro and in vivo studies to support the development of its CAR exosome therapy. Initial in vitro studies are expected to be completed in Q3 CY25 and in vivo studies in Q4 CY25. › On 18 June 2025, INOVIQ announced a major milestone in its CAR-exosome therapeutic program where its optimised CAR-NK-exosomes demonstrated exceptional in vitro efficacy, killing 88% of triplenegative breast cancer (TNBC) and non-small cell lung cancer cells in vitro within 96 hours. In real-time xCELLigence assays, CAR-NK-EVs at a dose of 2.5 million EVs per cell achieved 87.8% cell death in TNBC cells and 87.9% in lung cancer cells. These data show the superior anti-proliferative and pro-death effects of CAR-NK-EVs in two cancer cell lines (in vitro), supporting their further development as a potential next-gen cell-free therapy for multiple cancer types. symptoms no symptoms Percent of samples correctly identified by EXO-OC Review of Operations Directors’ Report Chairman’s Letter CEO’s Report Financial Report Shareholder Information 11 Annual Report 2025
RkJQdWJsaXNoZXIy MjE2NDg3